Centro Hepato-Bilio-Pancreático e de Transplantação
Permanent URI for this community
Browse
Browsing Centro Hepato-Bilio-Pancreático e de Transplantação by Issue Date
Now showing 1 - 10 of 70
Results Per Page
Sort Options
- A Vida Segura por um FioPublication . Matias, AAEsta é uma história diferente, simples, real e dramática, quase a raiar o inverosímil. É um caso de transculturalidade, de como a herança social pode determinar um indivíduo doente internado num serviço de saúde, longe da sua terra, da sua família, desenraizado do seu meio, desesperadamente agarrado às suas crenças.
- Pyoderma Gangrenosum Associated with Sclerosing Cholangitis, Type 1 Diabetes Mellitus and Ulcerative ColitisPublication . Catorze, M; Pereira, F; Fonseca, F; Morbey, A; Assis Pacheco, FWe describe the case of a 22-year-old black female with type 1 diabetes mellitus diagnosed when she was 12 years old. She first presented (March 1994) with pustules and ulcerations on the upper and lower limbs, trunk and scalp at the age 17. The diagnosis of pyoderma gangrenosum was made. Since presentation, changes in liver function were detected and subsequent study led to the diagnosis of sclerosing cholangitis. The diagnosis of ulcerative colitis was made after colonoscopy. Partial response was obtained with minocycline and clofazimine, but treatment with 5-aminosalicylic acid achieved no improvement of the ulcerations. Liver transplantation, followed by immunosuppressive therapy led to complete regression of the cutaneous lesions.
- Adesão nos Doentes TransplantadosPublication . Telles-Correia, D; Barbosa, A; Mega, I; Barroso, E; Monteiro, ECom base na literatura existente abordam-se os principais aspectos psiquiátricos relacionados com a adesão no transplante. Projectam-se vários modelos teóricos que podem ser utilizados no âmbito da adesão, entre os quais se destacam o modelo da hipótese cognitiva da adesão (Ley), o modelo de crenças da saúde (Rosenstock, Becker) e o modelo de autoregulação de Leventhal e propõe-se um modelo que se adequa ao doente transplantado. Não sendo possível uma classificação mono dimensional da adesão, consideraram-se várias características como a temporalidade (inicial, intermédia ou contínua), a frequência (ocasional, intermitente, persistente ou completa), a motivação (acidental, vulnerável ou decidida) e a certeza diagnóstica (definitiva, provável, possível ou pouco provável). Dos métodos para a medição da adesão podemos classificá-los como directos: observação directa da toma dos comprimidos, medição da concentração de fármaco no sangue, uso de marcadores incorporados nos comprimidos e de embalagens electrónicas; e indirectos: autorelato do doente, relato do médico assistente. Sugerese aquele que mais se adequa ao doente transplantado. A não adesão em doentes transplantados é muito frequente sendo a sua prevalência média de 25,28% e pode ser influenciada por diversos factores nomeadamente, demográficos (idade, estado civil, sexo, raça e nível socioeconómico), psiquiátricos e psicológicos (depressão, perturbações de personalidade, atraso mental, alcoolismo, crenças da doença, locus de controlo) e outros (custo da medicação, história de transplante prévio).
- Coping nos Doentes TransplantadosPublication . Telles-Correia, D; Mega, I; Barbosa, A; Barroso, E; Monteiro, EO desenvolvimento teórico dos Mecanismos de Coping (MC) tem como base uma dialéctica relacionada com os seus principais factores determinantes: individuais e situacionais (na base das duas abordagens do coping: disposicional e constitucional). Actualmente a classificação dos MC mais utilizada é baseada em duas dimensões: coping focado na emoção, e coping focado na resolução de problemas. Considera-se essencial que os métodos de classificação dos MC tenham em conta a coexistência de elementos disposicionais estáveis com uma variabilidade situacional dos MC. São abordados alguns instrumentos de medição de coping, baseados em diferentes pressupostos teóricos. O coping pode influenciar a saúde através de vários mecanismos (sistema neuroendócrino, comportamentos relacionados com os riscos para a saúde e adesão terapêutica) e é incluído em dois dos principais modelos teóricos de saúde (Moos & Schaefer e modelo de Leventhal). Com base numa revisão da literatura, concluiu-se que os estilos de coping mais prevalentes no pré transplante foram: aceitação, coping activo, e procura de suporte, sendo os menos utilizados: auto culpabilização e evitação. No pós transplante o coping activo e procura de suporte continuam a ser os estilos de coping preferenciais, a par da confrontação, autoconfiança, recurso à religião e coping focado no problema. Os estilos de coping (Evasivo, Emotivo, Fatalistico) estão associados a uma menor capacidade de controlo pessoal sobre a doença, a confrontação a uma maior qualidade de vida, o evitamento à redução da qualidade de vida e ao aumento dos níveis de depressão e a negação ao aumento da não adesão. A compreensibilidade, a sensação de controlo sobre a doença, os estilos de coping «relacionados com a expressão dos afectos» e a negação variam ao longo da evolução do doente transplantado.
- When Does Quality of Life Improve After Liver Transplantation? A Longitudinal Prospective StudyPublication . Telles-Correia, D; Barbosa, A; Mega, I; Mateus, E; Monteiro, EOBJECTIVES: We sought to investigate the improvement in quality of life (mental and physical components) at 1 and 6 months after liver transplantation. METHODS: A sample of liver transplant candidates (n = 60), comprising consecutive patients attending outpatient clinics of a liver transplantation central unit (25% of the patients had familial amyloid polyneuropathy [FAP] and the remaining patents had chronic liver diseases), was assessed by means of the Short Form (SF)-36, Portuguese-validated version, a self-rating questionnaire developed by the Medical Outcome Trust, to investigate certain primary aspects of quality of life, at 3 times: before, and at 1 and 6 months after transplantation. RESULTS: We observed a significant improvement in quality of life (both mental and physical components) by 1 month after transplantation. Between the first month and the sixth month after transplantation, there also was an improvement in the quality of life (both mental and physical components), although only the physical components of quality of life was significantly improved. CONCLUSIONS: Our findings suggested that quality of life improved early after liver transplantation (1 month). Between the first and the sixth months, there only was a significant improvement in the physical quality of life.
- Leflunomide and Polyomavirus-Associated Nephropathy in Renal TransplantPublication . Ferreira, AC; Ferreira, A; Possante, M; Sousa, J; Viana, H; Carvalho, H; Nolasco, FPolyomavirus nephropathy is a major complication in renal transplantation, associated with renal allograft loss in 14 to 80% of cases. There is no established treatment, although improvement has been reported with a variety of approaches. The authors report two cases of polyomavirus infection in renal allograft recipients. In the first case, a stable patient presented with deterioration of renal function, worsening hypertension and weight gain following removal of ureteral stent placed routinely at the time of surgery. Ultrasound examination and radiology studies revealed hydronephrosis due to ureteral stenosis. A new ureteral stent was placed, but renal function did not improve. Urinary cytology revealed the presence of decoy cells and polyomavirus was detected in blood and urine by qualitative polymerase chain reaction. Renal biopsy findings were consistent with polyomavirus -associated nephropathy. In the second case, leucopaenia was detected in an asymptomatic patient 6 months after transplantation. Mycophenolate mophetil dosage was reduced but renal allograft function deteriorated, and a kidney biopsy revealed polyomavirus -associated nephropathy, also with SV40 positive cells. In both patients immunosuppression with tacrolimus was reduced, mycophenolate mophetil stopped and intravenous immune globulin plus ciprofloxacin started. As renal function continued to deteriorate, therapy with leflunomide (40 mg/day) was associated and maintained during 5 and 3 months respectively. In the first patient, renal function stabilised within one month of starting leflunomide and polymerase chain reaction was negative for polyomavirus after 5 months. A repeated allograft biopsy 6 months later showed no evidence of polyomavirus nephropathy. In the second patient, polyomavirus was undetectable in blood and urine by polymerase chain reaction after 3 months of leflunomide treatment, with no evidence of polyomavirus infection in a repeated biopsy 6 months after beginning treatment.
- Sirolimus-Induced Drug Fever in a Renal Transplant Patient: a Case ReportPublication . Aires, I; Carvalho, D; Remédio, F; Possante, M; Ferreira, A; Pinto, JR; Nolasco, F; Ribeiro Santos, JHerein we have described the case of a male renal transplant recipient who developed drug fever apparently related to sirolimus. He had been stable under an immunosuppressive regimen of tacrolimus and mycophenolate mofetil, but developed acute cellular rejection at 5 years after transplantation due to noncompliance. Renal biopsy showed marked interstitial fibrosis, and immunosuppression was switched from mycophenolate to sirolimus, maintaining low tacrolimus levels. One month later he was admitted to our hospital for investigation of intermittently high fever, fatigue, myalgias, and diarrhea. Physical examination was unremarkable and drug levels were not increased. Lactic dehydrogenase and C-reactive protein were increased. The blood cell count and chest radiographic findings were normal. After extensive cultures, he was started on broad-spectrum antibiotics. Inflammatory markers and fever worsened, but diarrhea resolved. All serologic and imaging tests excluded infection, immune-mediated diseases, and malignancy. After 12 days antibiotics were stopped as no clinical improvement was achieved. Drug fever was suspected; sirolimus was replaced by mycophenolate mofetil. Fever and other symptoms disappeared after 24 hours; inflammatory markers normalized in a few days. After 1 month the patient was in good health with stable renal function. Although infrequent, the recognition of drug fever as a potential side effect of sirolimus may avoid unnecessary invasive diagnostic procedures. Nevertheless, exclusion of other common causes of fever is essential.
- Psychosocial Determinants of Quality of Life 6 Months After Transplantation: Longitudinal Prospective StudyPublication . Telles-Correia, D; Barbosa, A; Mega, I; Mateus, E; Monteiro, EOBJECTIVES: We sought to investigate the psychosocial determinants of quality of life at 6 months after transplantation. METHODS: A sample of liver transplant candidates (n = 60), composed of consecutive patients (25% with familial amyloid polyneuropathy [FAP]) attending outpatient clinics was assessed in the pretransplant period using the Neo Five Factor Inventory, Hospital Anxiety and depression Scale (HADS), Brief COPE, and SF-36, a quality-of-life, self-rating questionnaire. Six months after transplantation, these patients were assessed by means of the SF-36. RESULTS: Psychosocial predictors where found by means of multiple regression analysis. The physical component of quality of life at 6 months after transplantation was determined based upon coping strategies and physical quality of life in the pretransplant period (this model explained 32% of variance). The mental component at 6 months after transplantation was determined by depression in the pretransplant period and by clinical diagnoses of patients. Because FAP patients show a lower mental component of quality of life, this diagnosis explained 25% of the variance. CONCLUSIONS: Our findings suggested that coping strategies and depression measured in the pretransplant period are important determinants of quality of life at 6 months after liver transplantation.
- Personalidade e TransplantePublication . Telles-Correia, D; Barbosa, A; Mega, IA associação entre o tipo de personalidade e vários aspectos relacionados com a doença médica tem sido objecto de abundante investigação. Os modelos teóricos de personalidade que, hoje em dia, são mais utilizados neste contexto são de dois tipos: o modelo de três factores (Neuroticismo, Extroversão e Psicoticismo) e o modelo de 5 factores (neuroticismo e extroversão, a conscenciosidade, agradabilidade, e a abertura à experiência). Os modelos que relacionam a personalidade com a doença médica situam-se entre três tipologias: Hiperreactividade induzida pela personalidade, Predisposição constitucional e Comportamentos deletérios induzidos pela personalidade. Na avaliação da personalidade no doente médico pode optar-se por vários tipos de abordagem: Abordagem Taxonómica vs Dimensional; Auto vs Hetero avaliação; Instrumentos específicos para uma população vs Inespecíficos. São explorados os argumentos que favorecem as várias formas de abordagem. Entre os vários instrumentos disponíveis para avaliar a personalidade destacam-se o NEO-PI nas suas diferentes versões (NEO-PI original, NEO-PI-R, NEO-FFI-60). O NEO-PI-R e o NEO-FFI-60 estão validados para a população portuguesa. Dos poucos estudos disponíveis sobre personalidade no transplante foi possível concluir que o neuroticismo se associava a uma menor qualidade de vida (física, mental, social) no período pós-transplante e a extroversão a uma maior qualidade de vida (física, social), que a personalidade de tipo D se associava a uma pior qualidade de vida e uma maior mortalidade e taxa de rejeição após o transplante e que as perturbações de personalidade não estavam relacionadas com um aumento da taxa de recaída no consumo de álcool em doentes transplantados por doença hepática alcoólica.
- Transplantation in Highly Sensitised Patients Treated with Intravenous Immunoglobulin and RituximabPublication . Ferreira, AC; Brum, S; Fernandes, V; Buinho, F; Viana, H; Alcântara, P; Ferreira, A; Candeias, N; Sousa, J; Lima, A; Carvalho, F; Trindade, H; Nolasco, FRenal transplant in highly sensitised patients is associated with increased morbidity. The aim of this retrospective study was to evaluate the clinical evolution of 30 highly sensitised deceased donor kidney transplants and the influence of different timing of B cell directed treatment and its importance in the outcome of these patients. All recipients had negative complement dependent lymphocytotoxicity cytotoxic T cell crossmatch and no identified anti human leucocyte antigen class I donor specific antibodies. T cell flow crossmatch was performed within 24h of transplantation with serum obtained pretransplant (historic, recent or baseline). Posttransplant flow crossmatch were performed prospectively starting on the 3rd posttransplantation day. The immunosuppressive regime included thymoglobulin, tacrolimus, mycofenolate mofetil and steroids. Positive flow crossmatch occurred in 20/29 patients by the 3rd posttransplantation day, and in 17/27 patients after the 3rd posttransplantation day. All patients were started on intravenous immunoglobulin before transplantation: in nine patients (group A) at 400mg/kg/day for five days; in the remaining 21 patients (group B), as a continued infusion of 2g/kg during 48h. In group A, Rituximab was added only in the presence of antibody mediated rejection; in group B, introduced on the 3rd posttransplantation day whenever a positive flow crossmatch (with serum obtained pre or posttransplant) was reported. Antibody mediated rejection was observed in 44.4% of patients in group A, and 19% of those in group B. Mean follow-up was 12.2±5.5 months. Overall allograft survival was 76.6%, 81% in group B, and 66.6% in group A. At last follow up, mean serum creatinine was 1.3±0.6 mg/dl. Renal transplantation with pretransplant positive flow crossmatch is highly associated with antibody mediated rejection, despite introduction of intravenous immunoglobulin pretransplantation. However high dose intravenous immunoglobulin for 48h plus Rituximab by the 3rd posttransplantation day reduce the incidence of antibody mediated rejection by more than 50% and allowed for allograft survival of 81% at one year, with an excellent renal function.